Asia Pacific Next Generation Sequencing Market Size, Growth, Share & Trends Analysis
Asia Pacific Next-generation Sequencing Market by Product Type (Consumables, Platforms, Bioinformatics), Technology (SBS, Nanopore), Workflow (Sequencing, Data Analysis), Services, Application (Drug Discovery, Diagnostic, Agriculture) - Forecast to 2030
OVERVIEW
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
The Asia Pacific Next-generation Sequencing Market, valued at US$3.11 billion in 2024, stood at US$3.40 billion in 2025 and is projected to advance at a resilient CAGR of 16.7% from 2025 to 2030, culminating in a forecasted valuation of US$7.38 billion by the end of the period. The Asia Pacific next-generation sequencing market is expanding due to the rapid growth in sequencing applications for oncology, rare disease diagnostics, infectious diseases, and broader precision medicine programs across high- and middle-income countries in the region. Market growth is supported by substantial public and private investment in genomics, including national genome and precision medicine initiatives in China, Japan, India, South Korea, Singapore, and Australia, alongside ongoing advances that are lowering sequencing costs and improving throughput and data analytics.
KEY TAKEAWAYS
-
By RegionThe Chinese next-generation sequencing market accounted for a 43.5% revenue share in 2024.
-
By OfferingsBy offering, the Asia Pacific next-generation sequencing market services segment is expected to register the highest growth.
-
Product Market, By TypeIn the products market, by type, the consumables segment is expected to dominate the market.
-
Services Market, By TypeIn the services market, by type, the sequencing market segment is expected to dominate the market.
-
Products Market, By End userIn the product market, by end user, the pharmaceutical & biotechnology companies segment is projected to grow at the fastest rate from 2025 to 2030.
-
Services Market, By End userIn the services market, by end user, the academic & research institutes segment is projected to grow at the fastest rate from 2025 to 2030.
-
By ApplicationBy application, the diagnostics segment is projected to grow at the fastest rate from 2025 to 2030.
-
Competitive LandscapeIllumina, Inc., Thermo Fisher Scientific, and BGI Genomics Co., Ltd. were identified as key players in the North American next-generation sequencing (NGS) market, given their strong market share and product footprint.
-
Competitive LandscapeCompanies, such as Wuxi, have distinguished themselves among startups and SMEs by securing strong footholds in specialized niche areas, underscoring their potential as emerging market leaders.
The next-generation sequencing market in Asia-Pacific is evolving into a global high-growth market, anchored by rapid clinical adoption, large-scale genomic initiatives, and a rising burden of cancer and genetic disorders across both mature and emerging health systems. NGS has become a core enabler of precision medicine in the region, supporting large-cohort sequencing, population genomics, and data-driven clinical decision-making in countries such as China, Japan, India, South Korea, Australia, and key Southeast Asian markets.
TRENDS & DISRUPTIONS IMPACTING CUSTOMERS' CUSTOMERS
The impact on stakeholders’ businesses in the Asia Pacific next-generation sequencing market is shaped by rapidly expanding healthcare infrastructure, strong government-backed genomic initiatives, and rising patient demand for affordable, personalized, data-driven care across diverse economies in the region. Hospitals and diagnostic laboratories, academic and government research institutes, and pharmaceutical and biotechnology companies in countries such as China, Japan, India, South Korea, and Australia are the primary adopters of NGS solutions as they scale precision oncology, reproductive health, infectious disease testing, and large population-genomics programs.
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
MARKET DYNAMICS
Level
-
Rising cancer burden and precision-oncology adoption
-
National genomics and precision-medicine initiatives
Level
-
Fragmented and limited reimbursement for NGS
Level
-
Population genomics and under-represented populations
-
Growth of NGS services, automation, and bioinformatics outsourcing
Level
-
Data integration, interoperability, and governance issues
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
Driver: Rising cancer burden and precision-oncology adoption
The Asia Pacific is seeing a sharp increase in cancer incidence, and countries such as China, Japan, South Korea, and Australia are actively embedding NGS into oncology pathways and clinical guidelines. Clinical oncology in the Asia Pacific next-generation sequencing market is expected to witness the fastest regional CAGR globally, driven by tumor profiling, liquid biopsy, and MRD testing. This sustained shift from single-gene tests to NGS panels is a core growth engine for the regional market.
Restraint: Fragmented and limited reimbursement for NGS
Reimbursement for NGS tests remains inconsistent across the Asia Pacific, with funded access largely restricted to a few cancers and only in certain countries such as Japan, Australia, and South Korea. Value-assessment and funding frameworks often do not fully capture the long-term benefits of NGS, leading to narrow coverage, prior-authorization hurdles, and siloed budgets that slow broader adoption.
Opportunity: Population genomics and under-represented populations
GenomeAsia 100K and related initiatives are generating large, ethnically diverse reference datasets for Asian populations, addressing long-standing under-representation in global genomics. These projects are opening opportunities for NGS suppliers, data analytics companies, and pharma companies to develop population-specific risk scores, diagnostics, and drug targets, and to extend precision-medicine benefits to communities historically left out of genomic research.
Challenge: Data integration, interoperability, and governance issues
Efforts to leverage NGS for precision medicine require harmonized health-data infrastructure, yet reviews across Asian countries highlight heterogeneous real-world data practices and fragmented databases. Precision-health planning in Taiwan, for example, must overcome challenges around integrating specimens and data and clarifying legal rules for combining AI with health information. These governance and interoperability gaps slow cross-institutional studies and limit the full value of NGS-derived insights.
ASIA PACIFIC NEXT GENERATION SEQUENCING MARKET: COMMERCIAL USE CASES ACROSS INDUSTRIES
| COMPANY | USE CASE DESCRIPTION | BENEFITS |
|---|---|---|
 |
SQC team of OIST (Japan) uses the high-throughput NovaSeq 6000 System to perform sequencing for evolutionary genomics studies of chordates and other marine life | High throughput | Sophisticated analysis |
Logos and trademarks shown above are the property of their respective owners. Their use here is for informational and illustrative purposes only.
MARKET ECOSYSTEM
The Asia Pacific next-generation sequencing market ecosystem comprises instrument and reagent suppliers such as Illumina, Thermo Fisher Scientific, Roche, QIAGEN, Agilent, MGI, BGI Genomics, Oxford Nanopore Technologies, and several strong regional players, alongside a growing base of bioinformatics and software providers, clinical and research laboratories, and healthcare end users. Technology vendors deliver sequencing platforms, consumables, automation, and data-analysis solutions that support high-throughput genomic testing, while hospitals, diagnostic laboratories, academic institutes, CROs, and biopharmaceutical companies integrate these tools into clinical diagnostics, public-health surveillance, population and translational research, and drug-development programs across the Asia Pacific region.
Logos and trademarks shown above are the property of their respective owners. Their use here is for informational and illustrative purposes only.
MARKET SEGMENTS
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
Asia Pacific NGS Market, By Offerings
In 2024, the product segment represented the largest share of the Asia Pacific next-generation sequencing market. Products continue to be the anchor of revenue, underpinned by robust demand from large hubs in China, Japan, South Korea, India, Singapore, and Australia for mid- to high-throughput sequencers, oncology-focused panels, library preparation kits, and automation systems. Meanwhile, regional sequencing and bioinformatics service providers-including many backed by domestic genomic initiatives- are scaling capacity for clinical oncology, reproductive health, infectious-disease surveillance, and population genomics, facilitating fast growth in NGS services.
Asia Pacific NGS Products Market, By Type
As of 2024, consumables are the largest and fastest-growing segment of the Asia Pacific NGS products market, reflecting the heavy, repeated use of reagents, flow cells, enrichment kits, and library-preparation components in high-volume labs across China, Japan, South Korea, India, Singapore, and Australia. Pre-existing precision medicine and screening programs by governments and health systems mean that ongoing consumables purchases will continue to be the main driver of Asia Pacific next-generation sequencing market.
Asia Pacific NGS Services Market, By Type
Sequencing services held the largest share of the Asia Pacific next-generation sequencing market and are expected to maintain their dominance due to demand from research institutes, cancer centers, and biopharmaceutical companies. Most whole-genome, exome, targeted panel, RNA-seq, and single-cell projects are outsourced by a large number of hospitals and laboratories in this region to various service providers rather than developing full in-house capacity.
Asia Pacific NGS Market, By Application
In 2024, drug discovery and development applications constitute one of the largest and dynamic segments of the Asia Pacific next-generation sequencing market. This segment is expected to be a key growing market in the next few years. By 2024, drug discovery and development applications constitute one of the largest and most dynamic segments of the Asia Pacific next-generation sequencing market and are expected to remain a key growth engine over the next several years.
REGION
China to be the fastest-growing country in the Asia Pacific NGS market during the forecast period
The China next-generation sequencing market is expected to grow strongly over the forecast period, underpinned by a national push to integrate genomics and precision medicine into routine care through successive Five-Year Plans, cancer-control programs, and large government-backed genome initiatives. Demand is further growing by intensive biopharmaceutical R&D and clinical trials that rely on next-generation sequencing for biomarker discovery and companion diagnostics, alongside a fast-expanding molecular diagnostics sector focused on precision oncology, rare genetic diseases, and infectious disease surveillance.
ASIA PACIFIC NEXT GENERATION SEQUENCING MARKET: COMPANY EVALUATION MATRIX
In the Asia Pacific next-generation sequencing market matrix, Illumina (Star) commands a leading position with a substantial installed base of high-throughput, benchtop, and clinical sequencing platforms, supported by a broad ecosystem of reagents, library preparation kits, and integrated data-analysis solutions that are widely deployed across academic centers, clinical laboratories, and biopharmaceutical organizations in the region. Takara Bio (Emerging Leader) is rapidly building visibility in the Asia Pacific through a differentiated NGS portfolio focused on high-performance library preparation chemistries, RNA-seq and single-cell solutions, and application-specific kits that are optimized for oncology, biomarker discovery, and reproductive health research.
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
KEY MARKET PLAYERS
- Illumina, Inc. (US)
- Thermo Fisher Scientific, Inc. (US)
- Agilent Technologies, Inc. (US)
- Takara Bio (Japan)
- Wuxi Biologics (China)
- BGI Group (China)
- MGI Tech Co., Ltd. (China)
- Novogene Co., Ltd. (China)
- Macrogen Inc. (South Korea)
MARKET SCOPE
| REPORT METRIC | DETAILS |
|---|---|
| Market Size in 2024 (Value) | USD 3.11 Billion |
| Market Forecast in 2030 (Value) | USD 7.38 Billion |
| Growth Rate | CAGR of 16.7% from 2025-2030 |
| Years Considered | 2023-2030 |
| Base Year | 2024 |
| Forecast Period | 2025-2030 |
| Units Considered | Value (USD Million/Billion) |
| Report Coverage | Revenue forecast, company ranking, competitive landscape, growth factors, and trends |
| Segments Covered |
|
| Countries Covered | China, Japan, India, South Korea, Australia, and Rest of Asia Pacific |
WHAT IS IN IT FOR YOU: ASIA PACIFIC NEXT GENERATION SEQUENCING MARKET REPORT CONTENT GUIDE
DELIVERED CUSTOMIZATIONS
We have successfully delivered the following deep-dive customizations:
| CLIENT REQUEST | CUSTOMIZATION DELIVERED | VALUE ADDS |
|---|---|---|
| Global NGS platform & reagents manufacturer (Asia Pacific focus) |
|
|
| Leading Asia Pacific university hospital / genomics center |
|
|
RECENT DEVELOPMENTS
- June 2025 : WuXi Biologics (China) launched Next-Generation Platform WuXiHigh 2.0 for High-Concentration Biologics with Protein Concentration Reaching 230 mg/ml
- July 2022 : BGI UK announced the launch of HotMPS sequencing chemistry and services in the UK.
- October 2022 : Takara Bio partnered with BioExcel Diagnostics to develop and validate a new, high-throughput, comprehensive method for detecting syndromic-based infectious diseases.
Table of Contents
Exclusive indicates content/data unique to MarketsandMarkets and not available with any competitors.
Methodology
This study on the Asia Pacific Next-generation Sequencing Market employed secondary sources, directories, and databases to gather pertinent information. To gather and validate important qualitative and quantitative data and evaluate market growth prospects, in-depth interviews were conducted with many primary respondents including key industry participants, subject-matter experts (SMEs), C-level executives from key market players, and industry consultants. After estimating the Asia Pacific Next-generation Sequencing Market using several research strategies, the size of the final market was obtained by triangulating data from primary research.
Secondary Research
The secondary sources referred to for this research study include publications from government sources. These include the Centers for Disease Control and Prevention (CDC), the US Food and Drug Administration (FDA), the World Health Organization (WHO), the American Cancer Society (ACS), the National Center for Biotechnology Information (NCBI), the National Institutes of Health (NIH), National Human Genome Research Institute (NHGRI), International Agency for Research on Cancer (IARC), National Institute for Infectious Diseases (IRCCS), Association for Clinical Genomic Science (ACGS), American Society of Human Genetics (ASHG), European Society of Human Genetics (ESHG), Asia Pacific Society of Human Genetics (APSHG), Nature Reviews Genetics, Nature Methods, Biotechnology and Biological Sciences Research Council (BBSRC), Organisation for Economic Co-operation and Development (OECD), Genome Research, National Cancer Institute (NCI), European Medicines Agency (EMA), Population Health Research Institute (PHRI), PubMed, World Bank, and the World Health Organization (WHO), among others. Secondary sources also included corporate & regulatory filings, such as annual reports, SEC filings, investor presentations, and financial statements; business magazines & research journals; press releases; and trade, business, and professional associations. Secondary data was collected and analyzed to arrive at the overall size of the global Asia Pacific Next-generation Sequencing Market , which was validated through primary research.
Primary Research
Extensive primary research was conducted after acquiring basic knowledge about the global Asia Pacific Next-generation Sequencing Market scenario through secondary research. Several primary interviews were conducted with market experts from the supply side, such as C-level and D-level executives, operational managers, marketing & sales managers of key manufacturers, distributors, and channel partners of companies providing NGS; experts from the demand side, such as personnel from academic & research institutes, hospitals, clinics and diagnostic labs, pharmaceutical & biopharmaceutical industries, CROs, and other end users. These interviews were conducted across six major regions, including North America, Europe, the Asia Pacific, Latin America, the Middle East, and Africa. Approximately 70% and 30% of the primary interviews were conducted with supply-side and demand-side participants, respectively. This primary data was collected through questionnaires, e-mails, online surveys, personal interviews, and telephonic interviews.
Market Size Estimation
Both top-down and bottom-up approaches were used to estimate and validate the total size of the Asia Pacific Next-generation Sequencing Market . These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:
Data Triangulation
To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.
Market Definition
NGS refers to non-Sanger-based, high-throughput DNA sequencing technologies. DNA strands can be sequenced simultaneously, yielding substantially more throughput and minimizing the need for fragment-cloning methods often used in the Sanger sequencing of genomes. NGS is fundamentally based on sequencing by synthesis (SBS), ion semiconductor sequencing, single-molecule real-time (SMRT) sequencing, and nanopore sequencing.
Stakeholders
- NGS instrument manufacturers, vendors, and distributors
- NGS service providers
- NGS bioinformatics/data analysis companies
- Research laboratories and academic institutes
- Venture capitalists and other government funding organizations
- Research and consulting firms
- Healthcare institutions (hospitals and diagnostic clinics)
- Pharmaceutical and biotechnology companies
- Academic and government research institutes
- Life science companies
Report Objectives
- To define, describe, and forecast the Asia Pacific Next-generation Sequencing Market based on offerings, product type, platform technology, product workflow, product end user, service type, service workflow, service end user, application, and region
- To provide detailed information regarding the major factors influencing the market growth (such as drivers, restraints, opportunities, and challenges)
- To strategically analyze micro markets with respect to individual growth trends, prospects, and contributions to the overall next-generation sequencing market
- To analyze the opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
- To forecast the size of the market segments with respect to six main regions, namely, North America, Europe, the Asia Pacific, Latin America, the Middle East, and Africa
- To profile the key players in the global Asia Pacific Next-generation Sequencing Market and comprehensively analyze their platforms, reagents, kits, consumables, and services portfolios, market positions, and core competencies
- To track and analyze competitive developments such as product & service launches, expansions, agreements, and collaborations in the next-generation sequencing market
- To benchmark players within the Asia Pacific Next-generation Sequencing Market using the ‘Company Evaluation Matrix' framework, which analyzes market players based on various parameters within the broad categories of business and service strategy
Need a Tailored Report?
Customize this report to your needs
Get 10% FREE Customization
Customize This ReportPersonalize This Research
- Triangulate with your Own Data
- Get Data as per your Format and Definition
- Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
- Any level of Personalization
Let Us Help You
- What are the Known and Unknown Adjacencies Impacting the Asia Pacific Next-generation Sequencing Market
- What will your New Revenue Sources be?
- Who will be your Top Customer; what will make them switch?
- Defend your Market Share or Win Competitors
- Get a Scorecard for Target Partners
Custom Market Research Services
We Will Customise The Research For You, In Case The Report Listed Above Does Not Meet With Your Requirements
Get 10% Free Customisation
Growth opportunities and latent adjacency in Asia Pacific Next-generation Sequencing Market